[2026 update] Publication patterns in the BPC-157 literature, examined

Publication patterns in the BPC-157 literature, examined Writing it up because I had to work it out twice and would rather nobody else did.

Putting the numbers in the first post, because a question about a compound without them turns into a question about somebody's impression of it.

BPC-157, monoisotopic mass near 4113.6 Da, 24 weeks of my own notes, and 8 lots from 4 suppliers with a purity figure on each. That is the whole basis of what follows.

What I want checked is the reasoning I have built on top of it, not the figures themselves.

The strongest argument against my own position on Publication patterns, stated as well as I can state it, since nobody else has yet.

Everything in the opening post holds. The case it does not cover is the one I have.

Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.

Publication patterns would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.

Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.

TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation and in the literature. Evidence about the full protein does not automatically apply to the fragment.

I checked the source rather than the summary, and they differ.

Thank you — that answers what I came here to find out.

Worth separating two things that post #5 runs together.

The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.

This follows post #9 rather than contradicting it.

Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.

Post #10 answers the question as asked. The question underneath it is different.

The version of Publication patterns that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.

BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.

Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.

If that reads as pedantic, it is, and it has saved me twice.

Worth separating two things that post #12 runs together.

Publication patterns is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.